BEST UNLIMITED TURBO LONG CERTIFICATE - ASTRAZENECA | Market Closed - Euronext Paris 17:30:00 03/05/2024 BST | ||
| 3.885 EUR | -1.52% |
|
| Current month | +2.24% | ||
| 1 month | +76.99% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/05/24 | 3.885 | -1.52% | 77 |
| 02/05/24 | 3.945 | +3.82% | 84 |
| 30/04/24 | 3.8 | -0.91% | 70 |
| 29/04/24 | 3.835 | -1.16% | 81 |
| 26/04/24 | 3.88 | +1.84% | 89 |
Real-time Euronext Paris
Last update May 03, 2024 at 05:30 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| 829PS | |
| ISIN | DE000SF1DWC4 |
| Date issued | 11/06/2021 |
| Strike | 8,806 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.92 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.815 € |
|---|---|
| Lowest since issue | 0.55 € |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
151.2
USD
Average target price
164.5
USD
Spread / Average Target
+8.76%
- Stock Market
- Certificates
- 829PS Certificat
